Cardiovascular Risk Factors / Clinical Lab Industry News / Diagnostics Industry

Troponin biomarker used for indicating risk of ‘silent strokes’

Troponin biomarker used for indicating risk of ‘silent strokes’The biomarkers troponin T and NT-proBNP appear to indicate risk for ‘silent’ strokes and other causes of mild brain damage that do not present symptoms.

Research from The Methodist Hospital in Texas has shown that high blood levels of the two biomarkers were linked to 3 times and 3.5 times the amount of damaged brain tissue.

Dr Christie Ballantyne, lead researcher, commented that we need to “assess the risk for heart attack, stroke, heart failure and also asymptomatic disease so we can start preventative efforts earlier.  Waiting to correct problems until after a symptomatic stroke may be too late.”

It may be that those patients who are classified in such high-risk groups may be called upon to begin anti-stroke treatment sooner.

An earlier study by the same organisation showed a strong relationship between blood levels of troponin T and NT-proBNP and symptomatic stroke.  The current study looked at the biomarkers and ‘subclinical,’ asymptomatic events in the brain.

The studies illustrate that the biomarkers can help identify those who are likely to have brain disease and potential stroke, giving doctors more time to help patients.

Data was taken from 1,100 participants; who had blood draws and two MRI scans 11 years apart, which looked for silent brain infarcts and white matter lesions caused by chronic inflammation. Analysis of results showed a strong relationship between high NT-proBNP and the chance of brain infarcts and white matter lesions. Participants which had the highest levels had as much as 3.5 times the number of brain infarcts and more white matter lesions than those with low levels of NT-pro-BNP. For patients with the highest levels of Troponin T, the number of brain infarcts and white matter lesions were as much as 3.0 times more.

Reference: www.sciencedaily.com

Line

Randox Laboratories provide two cardiac arrays capable of detecting mutiple cardiac markers, including troponin I and II, H-FABP and Myoglobin.  For more information, visit the Biochip Immunoassays section of the website.

 

Leave a Reply

Your email address will not be published. Required fields are marked *

*